Global Brachytherapy Market - 2023-2030

Global Brachytherapy Market - 2023-2030

The Global Brachytherapy Market reachedUS$ 0.8 Billion in 2022 and is expected to reach US$ 1.5 Billion by 2030, growing with a CAGR of 8.1%during the forecast period 2023-2030.

Brachytherapy treatment uses radioactive material sealed inside a seed, pellet, wire, or capsule implanted in the body using a needle or catheter. The radiation given off by this source damages the DNA of nearby cancer cells. Brachytherapy is most commonly used to treat prostate cancer.

It also can be used for gynecologic cancers such as cervical cancer and uterine (endometrial) cancer, as well as breast cancer. Brachytherapy can also be utilized in others cancers including lung cancer, rectal cancer, eye cancer, and skin cancer. Furthermore, the increase in the prevalence of cancer can elevate the brachytherapy market size.

Due to the massive rise in technological advancements in countries like the U.S. and Canada, the market experience increased demand from North American regions. Significantkey players like Perspective Therapeutics, Theragenics, Eckert & Ziegler, Civco Medical Solutions, and others are actively operating in the market.

Dynamics

The Growing Incidence of Prostate Cancer can Elevate the Market Growth

The increase in the incidence of prostate cancer can elevate the growth of the market. For instance, according to the American Cancer Society about 288,300 new cases of prostate cancer are estimated in the United States in 2023 and around 34,700 deaths are estimated from prostate cancer.

Prostate cancer is more likely to develop in older men and in non-hispanic black men. About 6 cases in 10 are diagnosed in men 65 or older, and it is rare in men under 40. The average age of men when they are first diagnosed is about 66 years. Brachytherapy procedure is used to implant radioactive seeds (pellets) into the prostate gland to kill prostate cancer cells.

The seeds may give off high or low amounts of radiation. Numerous patients with prostate cancer require brachytherapy. Thus, above mentioned factors demonstrate that an increase in prostate cancer can elevate market growth.

Rise in the Number of Breast Cancer Cases can Boost the Market Growth

An increase in the number of breast cancer cases can accelerate the growth of the market.For instance, according to CDC, each year in the United States, about 264,000 cases of breast cancer are diagnosed in women and about 2,400 in men. About 42,000 women and 500 men in the U.S. die each year from breast cancer. Black women have a higher rate of death from breast cancer than white women.

Interstitial brachytherapy is performed on breast cancer patients. Several small, hollow tubes called catheters are inserted into the breast around the area at the site of the cancer that has to be removed and are left in place for several days. Radioactive pellets are inserted into the catheters for short periods of time each day and then removed. Thus, these aforementioned factors shows the rise in the market growth.

Side Effects Associated with the Treatment can Decline the Market Growth

Side effects of brachytherapy can include swelling, bruising, bleeding, or pain and discomfort at the spot where the radiation was delivered. Brachytherapy used for gynecologic or prostate cancer can lead to short-term urinary symptoms, including incontinence or pain in urination.

Brachytherapy for these cancers can also lead to diarrhea, constipation, and rectal bleeding. Prostate brachytherapy can occasionally cause erectile dysfunction. These above mentioned factors may restrain the market growth.

Segment Analysis

The global brachytherapy market is segmented based on type, indication type, end-user and region.

High Dose Rate Brachytherapy SegmentAccounted for Approximately 39.6% of the Brachytherapy Market Share

High dose rate brachytherapy segment is expected to hold a significant position in the brachytherapy market share. In high dose-rate brachytherapy, the tumour is exposed to a high dosage of radiation but the surrounding organs are greatly spared. Radiation that is administered at a high dose-rate or at a high dose per fraction is known to be particularly sensitive to prostate cancer.

Lower toxicity than with low dosage-rate implants is achieved through quick administration and good dose conformity. Several researches have suggested that the high or intermediate risk patients who are suitable should be provided with high dose rate brachytherapy (HDR) in combination with external beam radiotherapy since it has a greater rate of cancer control than external beam alone.

A single 15 Gy HDR in conjunction with 40–50 Gy external beam radiation yields a disease-free survival rate of over 90% for moderate risk and 80% for high risk, despite the fact that different doses and fractionations have been employed. Thus, the rising research studies by the researchers are expected to raise the growth of the segment.

Geographical Penetration

North America Accounted for Approximately 42.1% of the Market Share in 2022.

North America is expected to hold a significant position in the brachytherapy market share. The increase in technological advancements in healthcare and the agreements by the companies can elevate the growth of the market in this region. For instance, on July 23, 2021, Elekta (EKTA-B.ST) announced that GenesisCare, a leading global provider of integrated cancer care, has ordered 27 Flexitron brachytherapy afterloader systems, including service agreements.

The cancer treatment devices will allow GenesisCare to continue to invest in the latest world-class technology while providing access to high-quality care to their patients throughout their U.S. centers. GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide, and Elekta is delighted to play a vital partnering role in achieving this mission. Thus, an increase in the strategic initiatives by the key players can elevate the growth of the market.

Competitive Landscape

The major global players in the brachytherapy market include Perspective Therapeutics, Theragenics, Eckert & Ziegler, Civco Medical Solutions, Mirion Technologies, Elekta AB, IsoAid, Varian Medical Systems, Inc., Prowess Inc., RaySearch Laboratories among others.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant influence on the brachytherapy market, posing unprecedented challenges to many countries. The delay in the diagnosis of cancers and also the delay in the treatment procedures have created a negative impact on the growth of the market. The reduction in the advancements and investments by the key companies has created a significant decline in the growth of the market. Thus, COVID-19 has created a negative impact on the growth of the market.

By Type
• High-Dose Brachytherapy
• Low-Dose Brachytherapy

By Indication Type
• Prostate Cancer
• Gynecological Cancer
• Breast Cancer
• Others

By End-User
• Hospitals
• Ambulatory Surgery Centers
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Key Developments
• On July 14, 2023, BEBIG Medical, a global provider of high-quality radiation therapy products, is pleased to announce its successful bid in the Ministry of Health (MOH) tender in Indonesia. BEBIG Medical has been awarded contracts to supply 6 units of HDR (high dose rate) brachytherapy equipment to hospitals across the country. This achievement highlights BEBIG Medical's commitment to delivering cutting-edge medical technology to support cancer treatment in Indonesia.
• On April 20, 2023, Elekta announced that an estimated two million brachytherapy treatments have been delivered by healthcare providers using Flexitron high dose rate (HDR) afterloader. One site that has contributed to this treatment milestone is Amsterdam University Medical Centers (Amsterdam UMC) in the Netherlands, which acquired the 1,000th Flexitron recently manufactured at Elekta’s facility in Veenendaal.
• On January 5, 2023, C4 Imaging LLC is pleased to announce that Isoray Medical, Inc. has received U.S. Food and Drug Administration (FDA) clearance for the use of C4 Imaging’s Sirius positive-signal MRI (Magnetic Resonance Imaging) Markers with Isoray’s Cesium-131, brachytherapy seeds.

Why Purchase the Report?
• To visualize the global brachytherapy market segmentation based on type, indication type, end-user, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of brachytherapy market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available in Excel consisting of key products of all the major players.

The global brachytherapy market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies